The DOI matches its OpenAlex record; 48 of the 48 references it cites were found in a registry or an index.
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
Open accessAbstract
BACKGROUND: The use of anthracyclines is limited by the occurrence of cardiotoxicity. In an effort to prevent this cardiotoxicity, different anthracycline derivates have been studied. OBJECTIVES: To determine the occurrence of cardiotoxicity with the use of different anthracycline derivates in cancer patients. SEARCH STRATEGY: We searched The Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 2, 2009), MEDLINE (1966 to 29 May 2009) and EMBASE (1980 to 2 June 2009). In addition, we searched reference lists of relevant articles, conference proceedings and ongoing-trials-databases. SELECTION CRITERIA: Randomised controlled trials (RCTs) in which different anthracycline derivates were compared in cancer patients (children and adults). DATA COLLECTION AND ANALYSIS: Two authors independently performed study selection, assessment of risk of bias and data-extraction including adverse effects. MAIN RESULTS: We identified five RCTs of varying quality addressing epirubicin versus doxorubicin (1036 patients) with the same dose. The meta-analysis showed no evidence for a significant difference in the occurrence of clinical heart failure between the treatment groups (RR = 0.36, 95% CI 0.12 to 1.11). However, there is some suggestion of a lower rate of clinical heart failure in patients treated with epirubicin.We identified two RCTs with varying quality addressing liposomal-encapsulated doxorubicin versus conventional doxorubicin (521 patients). The meta-analysis showed a significantly lower rate of both clinical heart failure and clinical and subclinical heart failure combined in patients treated with liposomal-encapsulated doxorubicin (RR = 0.20, 95% CI 0.05 to 0.75 and RR = 0.38, 95% CI 0.24 to 0.59 respectively). It should be noted that in one of the studies patients in the liposomal-encapsulated doxorubicin group received a higher cumulative anthracycline dose than patients in the doxorubicin group.For the other possible combinations of different anthracycline derivates only one RCT (epirubicin versus liposomal-encapsulated doxorubicin) or no RCT was identified. AUTHORS' CONCLUSIONS: We are not able to favour either epirubicin or doxorubicin when given with the same dose. Based on the currently available evidence on heart failure, we conclude that in adults with a solid tumour liposomal-encapsulated doxorubicin should be favoured over doxorubicin. For both epirubicin versus doxorubicin and liposomal-encapsulated doxorubicin versus conventional doxorubicin no conclusions can be made about the effects of treatment in children treated with anthracyclines and also not in patients diagnosed with leukaemia. More research is needed. For other combinations of anthracycline derivates not enough evidence was available to make definitive conclusions about the occurrence of cardiotoxicity in patients treated with anthracyclines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
Kremer, L. C. M., van Dalen, E. C., Offringa, M., Ottenkamp, J., & Voûte, P. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.191 · Cited by 399
Self-citationNorthfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., & Kaplan, L. D. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04152.x · Cited by 378
Kremer, L. C. M., van der Pal, H. J. H., Offringa, M., van Dalen, E. C., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf167 · Cited by 354
Self-citationCARDIAC TOXICITY OF DAUNORUBICIN
Bonadonna, G., Monfardini, S., Marmont, A., Damasio, E., & Rossi, F. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92093-5 · Cited by 348
van Dalen, E. C., van der Pal, H. J. H., Kok, W. E. M., Caron, H. N., & Kremer, L. C. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.005 · Cited by 284
Self-citationJain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., Currie, V, Schwartz, W., Cassidy, C., Petroni, G. R., & Young, C. W. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.818 · Cited by 251
Kremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Self-citation(1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.976 · Cited by 167
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 167
Cardiotoxicity of Cancer Chemotherapy: Implications for Children
Simbre, V. C., Duffy, S. A., Dadlani, G. H., Miller, T. L., & Lipshultz, S. E. (2005) · Pediatric Drugs · doi:10.2165/00148581-200507030-00005 · Cited by 166
Nousiainen, T., Jantunen, E., Vanninen, E., & Hartikainen, J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600346 · Cited by 165
Mouridsen, H. T., Bastholt, L., Somers, R., Santoro, A., Bramwell, V. H. C., Mulder, J. H., van Oosterom, A. T., Buesa, J., Pinedo, H. M., Thomas, D., et al. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90089-7 · Cited by 154
Rifkin, R. M., Gregory, S. A., Mohrbacher, A. M., & Hussein, M. A. (2006) · Cancer · doi:10.1002/cncr.21662 · Cited by 136
Anticancer Agents and Cardiotoxicity
Ng, R. C. H., Better, N., & Green, M. D. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.001 · Cited by 127
Pérez, D. J., Harvey, V. J., Robinson, B. A., Atkinson, C. H., Dady, P. J., Kirk, A. R., Evans, B. D., & Chapman, P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.12.2148 · Cited by 116
Nielsen, O. S., Dombernowsky, P., Mouridsen, H. T., Crowther, D., Verweij, J., Buesa, J., Steward, W. P., Daugaard, S., Glabbeke, M. M. V., Kirkpatrick, A., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.735 · Cited by 105
Mandelli, F., Petti, M. C., Ardia, A., Pietro, N. D., Raimondo, F. D., Ganzina, F., Falconi, E., Geraci, E., Ladogana, S., Latagliata, R., et al. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90181-c · Cited by 98
Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla, C., Rossi, A., Bonfante, V., Ferrari, L., Villani, F., Crippa, F., & Bonadonna, G. (1986) · PubMed · Cited by 94
A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer
Hortobágyi, G. N., Yap, H. Y., Kau, S., Fraschini, G., Ewer, M. S., Chawla, S. P., & Benjamin, R. S. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198902000-00014 · Cited by 88
Cardiotoxicity of epirubicin and doxorubicin: A double‐blind randomized study
Lahtinen, R., Kuikka, J. T., Nousiainen, T., Uusitupa, M. I. J., & Länsimies, E. (1991) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1991.tb01543.x · Cited by 70
Moser, E. C., Noordijk, E. M., Carde, P. P., Tirelli, U., Baars, J. W., Thomas, J., Bron, D., Meerwaldt, J. H., Glabbeke, M. M. V., Raemaekers, J. M. M., et al. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.038 · Cited by 56
Avilés, A., Neri, N., Nambo, M. J., et al. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500063229 · Cited by 55
Gasparini, G., Fior, S. D., Panizzoni, G. A., Favretto, S., & Pozza, F. (1991) · American Journal of Clinical Oncology · doi:10.1097/00000421-199102000-00009 · Cited by 53
New anthracycline analogs in advanced breast cancer
Bonfante, V., Ferrari, L., Brambilla, C., Rossi, A., Villani, F., Crippa, F., Valagussa, P., & Bonadonna, G. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90149-5 · Cited by 41
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub2 · Cited by 41
Self-citationMeinardi, M. T., van der Graaf, W. T. A., Gietema, J. A., van den Berg, M. P., Sleijfer, D. T., de Vries, E. G. E., Haaksma, J., Boomsma, F., & van Veldhuisen, D. J. (2002) · Heart · doi:10.1136/heart.88.1.81 · Cited by 40
Lopez, M., Papaldo, P., Lauro, L. D., Vici, P., Carpano, S., & Conti, E. (2009) · Oncology · doi:10.1159/000226671 · Cited by 39
Nielsen, O. S., Dombernowsky, P., Mouridsen, H. T., Daugaard, S., Glabbeke, M. M. V., Kirkpatrick, A., & Verweij, J. (2000) · Sarcoma · doi:10.1155/s1357714x00000062 · Cited by 32
Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
Neri, B., Cini-Neri, G., Bandinelli, M., Pacini, P., Bartalucci, S., & Ciapini, A. (1989) · PubMed · Cited by 31
Heidemann, E., Steinke, B., Hartlapp, J. H., Schumacher, K. R., Possinger, K., Kunz, S., Neeser, E., Ingersleben, G. V., Hossfeld, D., & Waldmann, R. (2009) · Onkologie · doi:10.1159/000216714 · Cited by 29
Hernádi, Z., Juhász, B., Póka, R., & Lampe, L. G. (1988) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(88)90008-2 · Cited by 27
Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma
Al‐Ismail, S., Whittaker, J. A., & Gough, J. E. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90123-4 · Cited by 27
Homesley, H. D., Harry, D. S., O’Toole, R. V., Hoogstraten, B., Franklin, E. W., Cavanagh, D., Nahhas, W. A., Smith, J. J., & Lovelace, J. (1992) · American Journal of Clinical Oncology · doi:10.1097/00000421-199204000-00007 · Cited by 27
Comparison of CHOP-B vs CEOP-B in ‘poor prognosis’ non-Hodgkin’s lymphomas. A randomized trial
Lena, M. D., Maiello, E., Lorusso, V., Brandi, M., Calabrese, P., Romito, S., Mazzei, A., & Marzullo, F. (1989) · Medical Oncology and Tumor Pharmacotherapy · doi:10.1007/bf02985240 · Cited by 22
Knobloch, K., Tepe, J., Rossner, D., Lichtinghagen, R., Lück, H., Busch, K. H., & Vogt, P. M. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.04.182 · Cited by 21
Bezwoda, W. R. (1986) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950140107 · Cited by 18
Bhutani, M., Kumar, L., Vora, A., Bhardwaj, N. K., Pathak, A. K., Singh, R., & Kochupillai, V. (2002) · American Journal of Hematology · doi:10.1002/ajh.10211 · Cited by 13
Doxorubicin and 4″-Epidoxorubicin in Combination Chemotherapy of Extensive Small Cell Lung Cancer
Nikkanen, T. A. V., Jakobsson, M., Jaürvinen, M., Liippo, K. K., Ojala, A., Paloheimo, S., & Nordman, E. (1988) · Acta Oncologica · doi:10.3109/02841868809090324 · Cited by 7
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Metadata
- Authors
- van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Elsevier BV
- Published
- 2010-05-11
- Issue
- 5
- Pages
- CD005006-CD005006
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2140172581
- Cited by
- 265
- References
- 48
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.